Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 12/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880980 | 1.00 | ALDH1A1 (0.55) | ALDH1A1SOAT1MEN1KMT2AMAPT | |
| SCHEMBL4880411 | 0.85 | ALDH1A1 (0.44) | ALDH1A1SOAT1MEN1KMT2AMAPT | |
| SCHEMBL4880406 | 0.85 | ALDH1A1 (0.44) | ALDH1A1SOAT1MEN1KMT2AMAPT | |
| SCHEMBL4553978 | 0.82 | KCNA3 (0.49) | MAPTKCNA3 | |
| SCHEMBL4553979 | 0.82 | KCNA3 (0.49) | MAPTKCNA3 | |
| SCHEMBL14482447 | 0.82 | KCNA3 (0.49) | MAPTKCNA3 | |
| SCHEMBL4872040 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SOAT1MEN1KMT2AMAPT | |
| SCHEMBL4872031 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SOAT1MEN1KMT2AMAPT | |
| SCHEMBL4871837 | 0.81 | KDM1A (0.44) | ALDH1A1SOAT1 | |
| SCHEMBL4871823 | 0.81 | KDM1A (0.44) | ALDH1A1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | ALDH1A1 2899/4885SOAT1 502/4885MEN1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.